Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Long-term Investments
Investments the company intends to hold for more than a year.
Evommune, Inc.NYSE: EVMN
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments rises 46513.9% from a year ago
Long-term investments stood at $96.96M at the end of Q1 FY2026, up 46513.9% from a year earlier and up 40.7% from the prior quarter.
Context
- Long-term investments amounted to 30.1% of total assets at the end of Q1 FY2026, up 29.7 pp from a year earlier.
- Long-term investments increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +46513.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 68.9M USD
- Year-over-year change
- +33026.9%
- 2-year CAGR
- +1720.1%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 68.9M | +33026.9% |
| FY2024 | 2024-12-31 | 208K | +0.0% |
| FY2023 | 2023-12-31 | 208K | — |
Long-term Investments vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 long-term investments of $96.96M is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +46513.9% is the highest of 5, against a peer median of -43.2%.
- Long-term investments amounts to 30.1% of total assets for EVMN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $156.87M | -23.3% | +294.1% | 7.2% | |
EVMNEvommune, Inc. | Mar 2026 | $96.96M | +46513.9% | — | 30.1% |
CLYMClimb Bio, Inc. | Mar 2026 | $36.74M | -63.2% | — | 24.1% |
| Mar 2026 | $4.51M | +61.2% | -50.4% | 3.5% | |
| Mar 2026 | $317K | — | — | 0.2% | |
FTREFortrea Holdings Inc. | Jun 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | -100.0% | +261.3% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVMN) | $0 | -43.2% | +261.3% | 0.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.